Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis.
Malik J, Valerianova A, Pesickova SS, Michalickova K, Hladinova Z, Hruskova Z, Bednarova V, Rocinova K, Tothova M, Kratochvilova M, Kaiserova L, Buryskova Salajova K, Lejsek V, Sevcik M, Tesar V. Malik J, et al. Among authors: tesar v. Front Cardiovasc Med. 2023 Jun 1;10:1130618. doi: 10.3389/fcvm.2023.1130618. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37324637 Free PMC article.
Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA - associated vasculitis.
Satrapova V, Sparding N, Genovese F, Karsdal MA, Bartonova L, Frausova D, Honsova E, Kollar M, Suchanek M, Koprivova H, Rysava R, Bednarova V, Tesar V, Hruskova Z. Satrapova V, et al. Among authors: tesar v. Front Immunol. 2023 Mar 20;14:1122972. doi: 10.3389/fimmu.2023.1122972. eCollection 2023. Front Immunol. 2023. PMID: 37020541 Free PMC article.
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
Podestà MA, Mescia F, Ricchiuto A, Smith R, Tedesco M, Cassia MA, Holle J, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Hruskova Z, Tesar V, Sabiu G, Gallieni M, Cid MC, Vaglio A, Harper L, Cozzolino M, Scolari F, Jayne D, Alberici F. Podestà MA, et al. Among authors: tesar v. Rheumatology (Oxford). 2023 Aug 1;62(8):2850-2854. doi: 10.1093/rheumatology/keac716. Rheumatology (Oxford). 2023. PMID: 36562566
Rituximab in Membranous Nephropathy.
Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Gauckler P, et al. Among authors: tesar v. Kidney Int Rep. 2021 Jan 13;6(4):881-893. doi: 10.1016/j.ekir.2020.12.035. eCollection 2021 Apr. Kidney Int Rep. 2021. PMID: 33912740 Free PMC article. Review.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. Among authors: tesar v. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Expanding options of supportive care in IgA nephropathy.
Maixnerova D, Hartinger J, Tesar V. Maixnerova D, et al. Among authors: tesar v. Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii47-ii54. doi: 10.1093/ckj/sfad201. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38053975 Free PMC article. Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: tesar v. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.
Floyd L, Bate S, Hadi Kafagi A, Brown N, Scott J, Srikantharajah M, Myslivecek M, Reid G, Aqeel F, Frausova D, Kollar M, Kieu PL, Khurshid B, Pusey CD, Dhaygude A, Tesar V, McAdoo S, Little MA, Geetha D, Brix SR. Floyd L, et al. Among authors: tesar v. J Am Soc Nephrol. 2023 Mar 1;34(3):505-514. doi: 10.1681/ASN.2022050581. Epub 2022 Nov 29. J Am Soc Nephrol. 2023. PMID: 36446430 Free PMC article.
596 results